Ipca Laboratories Ltd

Ipca Laboratories Ltd

₹ 1,338 -1.06%
19 Apr - close price
About

Ipca Laboratories is engaged in the manufacturing and marketing of pharmaceuticals.(Source : 201903 Annual Report Page No: 68)

Key Points

Integrated nature of operations
Ipca Laboratories is a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments. [1]
IPCA is among India’s top 20 pharmaceutical companies. [2]

Business segments FY22:
API Business (25%) [3]
Ipca produces over 80 APIs, nearly 79% of the APIs and Intermediates business is from exports making them one of India’s top exporters of APIs, serving over 100 countries around the globe. The core strategic focus has been on backward integration, resulting in superior supply chain reliability and cost competitiveness [4] [1] [5]

  • Market Cap 33,944 Cr.
  • Current Price 1,338
  • High / Low 1,375 / 670
  • Stock P/E 61.7
  • Book Value 245
  • Dividend Yield 0.30 %
  • ROCE 11.3 %
  • ROE 8.57 %
  • Face Value 1.00

Pros

Cons

  • Dividend payout has been low at 13.6% of profits over last 3 years

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
1,315 1,041 1,479 1,424 1,328 1,178 1,478 1,495 1,440 1,402 1,486 1,663 1,507
966 824 1,085 1,065 1,017 996 1,223 1,224 1,229 1,226 1,189 1,354 1,233
Operating Profit 349 217 394 359 312 182 255 270 211 176 298 309 273
OPM % 27% 21% 27% 25% 23% 15% 17% 18% 15% 13% 20% 19% 18%
16 20 14 15 13 13 18 36 24 33 43 36 17
Interest 2 2 1 1 1 3 7 9 10 18 31 39 27
Depreciation 48 49 50 50 51 54 55 56 58 59 60 61 63
Profit before tax 315 186 356 322 272 137 211 240 166 132 250 245 200
Tax % 18% 18% 20% 20% 20% 20% 34% 31% 31% 36% 33% 34% 32%
260 151 285 258 218 110 140 166 115 85 167 162 137
EPS in Rs 10.25 5.97 11.22 10.16 8.60 4.34 5.52 6.53 4.54 3.34 6.57 6.39 5.40
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
2,329 2,778 3,235 3,088 2,804 3,102 3,193 3,606 4,338 5,114 5,405 5,775 6,057
1,865 2,216 2,498 2,556 2,526 2,666 2,748 2,909 3,419 3,596 4,164 4,860 5,002
Operating Profit 465 562 737 532 277 436 446 697 918 1,518 1,241 914 1,056
OPM % 20% 20% 23% 17% 10% 14% 14% 19% 21% 30% 23% 16% 17%
12 17 21 32 26 19 39 54 64 61 53 111 130
Interest 42 34 28 29 31 26 27 21 19 11 10 46 114
Depreciation 65 84 101 177 161 171 174 172 179 188 210 229 244
Profit before tax 369 461 629 358 111 258 283 557 785 1,380 1,074 750 827
Tax % 24% 28% 24% 28% 17% 27% 18% 18% 17% 17% 20% 33%
280 331 477 256 93 188 233 455 652 1,141 860 506 550
EPS in Rs 11.13 13.13 18.91 10.15 3.67 7.46 9.24 18.00 25.82 44.97 33.91 19.93 21.70
Dividend Payout % 14% 15% 13% 5% 0% 7% 5% 8% 10% 9% 12% 20%
Compounded Sales Growth
10 Years: 8%
5 Years: 13%
3 Years: 10%
TTM: 8%
Compounded Profit Growth
10 Years: 4%
5 Years: 16%
3 Years: -9%
TTM: 4%
Stock Price CAGR
10 Years: 13%
5 Years: 23%
3 Years: 7%
1 Year: 59%
Return on Equity
10 Years: 15%
5 Years: 17%
3 Years: 16%
Last Year: 9%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 25 25 25 25 25 25 25 25 25 25 25 25 25
Reserves 1,237 1,545 1,956 2,208 2,258 2,450 2,670 3,111 3,640 4,727 5,450 5,852 6,180
601 617 595 929 865 716 628 444 474 236 776 1,440 1,657
467 522 641 662 756 777 785 877 1,045 1,021 1,186 1,129 1,250
Total Liabilities 2,330 2,709 3,217 3,824 3,905 3,968 4,108 4,458 5,185 6,010 7,438 8,447 9,112
913 1,075 1,306 1,753 1,977 1,946 1,855 1,740 1,841 1,869 2,153 2,479 2,507
CWIP 95 129 165 267 129 95 73 66 84 182 297 123 128
Investments 43 22 29 82 97 212 216 322 649 868 1,339 1,057 2,689
1,280 1,482 1,717 1,722 1,702 1,716 1,964 2,329 2,611 3,092 3,650 4,789 3,789
Total Assets 2,330 2,709 3,217 3,824 3,905 3,968 4,108 4,458 5,185 6,010 7,438 8,447 9,112

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
319 387 515 455 696 271 324 496 561 1,096 832 762
-249 -261 -362 -686 -214 -146 -119 -123 -499 -560 -812 -710
-69 -81 -138 255 -414 -156 -130 -223 -139 -307 426 506
Net Cash Flow 1 45 14 25 68 -31 74 150 -76 229 446 559

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 54 55 51 42 57 59 68 64 71 55 56 59
Inventory Days 267 245 271 293 290 288 286 332 312 350 364 293
Days Payable 94 89 109 97 145 128 136 146 133 121 101 80
Cash Conversion Cycle 227 211 213 238 203 219 218 250 250 284 319 272
Working Capital Days 118 113 98 107 86 95 109 113 117 123 130 123
ROCE % 24% 24% 27% 13% 4% 9% 9% 17% 20% 30% 19% 11%

Shareholding Pattern

Numbers in percentages

1 Recently
Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
46.29% 46.29% 46.29% 46.29% 46.29% 46.29% 46.29% 46.29% 46.29% 46.29% 46.29% 46.30%
17.81% 18.46% 12.34% 11.02% 10.61% 10.57% 10.46% 10.58% 10.05% 9.86% 10.27% 10.51%
25.12% 25.24% 30.02% 32.70% 33.49% 33.46% 33.71% 33.74% 34.86% 34.72% 34.19% 34.05%
0.22% 0.22% 0.24% 0.24% 0.24% 0.32% 0.32% 0.32% 0.32% 0.32% 0.32% 0.32%
10.57% 9.80% 11.11% 9.75% 9.37% 9.34% 9.22% 9.06% 8.46% 8.80% 8.93% 8.82%
No. of Shareholders 1,05,42895,2391,06,7791,15,3351,10,8181,11,0431,08,1771,10,29699,88995,93082,80981,165

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls